On July 31, 2025, Oncotelic Therapeutics, Inc. entered into a Securities Purchase Agreement with Mast Hill Fund, issuing a convertible note of $560,000 at an interest rate of 10%, which can convert into shares at $0.07 each. Additionally, they have an option for Mast Hill to purchase up to $25 million in stock over two years based on certain conditions.